Compare GTIM & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | IOBT |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.7M |
| IPO Year | 2013 | 2021 |
| Metric | GTIM | IOBT |
|---|---|---|
| Price | $1.21 | $0.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 20.4K | ★ 6.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $142,315,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.50 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $1.10 | $0.03 |
| 52 Week High | $2.24 | $2.79 |
| Indicator | GTIM | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 22.09 |
| Support Level | $1.16 | N/A |
| Resistance Level | $1.29 | $0.22 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 88.89 | 7.91 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.